Ken Griffin Regulus Therapeutics Inc. Put Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$1.79 - $2.8 $7,876 - $12,320
-4,400 Reduced 34.92%
8,200 $14,000
Q1 2024

May 15, 2024
BUY
$1.13 - $2.88 $11,864 - $30,240
10,500 Added 500.0%
12,600 $36,000
Q4 2023

Feb 14, 2024
BUY
$1.21 - $1.44 $2,420 - $2,880
2,000 Added 2000.0%
2,100 $2,000
Q2 2023

Aug 14, 2023
BUY
$0.87 - $1.75 $87 - $175
100 New
100 $0
Q4 2022

Feb 14, 2023
BUY
$1.17 - $1.85 $1,521 - $2,405
1,300 New
1,300 $1,000

Others Institutions Holding RGLS

# of Institutions
65
Shares Held
52.6M
Call Options Held
155K
Put Options Held
34.2K
View Full List

About Regulus Therapeutics Inc.

RGLS Quotes by TradingView
  • Ticker RGLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,634,400
  • Market Cap $23.4M
  • Description
  • Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...
More about RGLS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email